Value of high-sensitivity C-reactive protein in low risk chest pain observation unit patients
Tóm tắt
High-sensitivity C-reactive protein (hs-CRP) rises with cardiac injury/ischemia. We evaluated its efficacy in aiding in the identification of an acute coronary syndrome (ACS) in patients (pts) admitted to the chest pain unit (CPU) for possible ACS. Retrospective study of all patients admitted to the CPU with chest pain who underwent hs-CRP testing as part of their CPU evaluation from January 2004 to October 2008. Patients were low risk for ACS (compatible symptoms, nondiagnostic initial ECG, and negative cTnI). ACS was diagnosed by positive functional study, cardiac catheterization, or cardiac event during 30-day follow-up. Positive hs-CRP was defined based on local laboratory levels (>1.0 mg/l or >3.0 mg/l), and population-based and prior study values >2.0 mg/l. Chi-square analysis was performed, and odds ratios (OR) are presented. Multivariate analysis was done to determine whether hs-CRP was independently associated with the diagnosis of ACS. Cardiac risk factors, demographics, and diagnosis of ACS were included in the model. Medians with IQR are presented for continuous data. Ninety-five percent confidence intervals are presented where applicable. A total of 958 patients had hs-CRP testing as part of their CPEU evaluation. Excluded from the analysis were 39 patients lost to follow-up. The final cohort comprised 478 (52%) women and 441 (48%) men with a median age of 56 (IQR 48-64). ACS was diagnosed in 128 (13.4%). The median cohort hs-CRP value was 2.2 mg/l (IQR 0.7, 5.8) and 2.3 mg/l (IQR 0.6, 5.9) in those with and without ACS, respectively. In the multivariate analysis hs-CRP was not independently associated with the diagnosis of ACS (0.99; 95% CI 0.98 - 1.01). In large patient cohort managed in a single-center CPU, measurement of hs-CRP did not enhance the diagnostic accuracy for ACS. Routine hs-CRP as a diagnostic tool should not be recommended in the CPU setting.
Tài liệu tham khảo
Amsterdam EA, Kirk JD, Bluemke DA, Diercks D, Farkouh ME, Garvey JL, Kontos MC, McCord J, Miller TD, Morise A, Newby LK, Ruberg FL, Scordo KA, THompson PD: Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain. A Scientific Statement From the American Heart Association. Circulation 2010, 122: 1756–76. 10.1161/CIR.0b013e3181ec61df
Correia LC, Andrade BB, Borges VM, Clarencio J, Bittencourt AP, Freitas R, Souza AC, Almeisa MC, Leal J, Estever JP, Barral-Netto M: Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes. Clin Chim Acta 2010, 411: 540–5. 10.1016/j.cca.2010.01.011
Burazor I, Vojdani A, Burazor M: Interrelationship of interleukin 6, C-reactive protein and Chlamydia pneumoniae IgG antibodies in patients with acute coronary syndromes. Vojnosanit Pregl 2008, 65: 425–33. 10.2298/VSP0806425B
Zairis MN, Adamopoulou EN, Manousakis SJ, Lytas AG, Bibis GP, Ampartizidou OS, Apostolatos CS, Anastassiadia FA, Hatzisavvas JJ, Argyrakis SK, Foussas SG: The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atherosclerosis 2007, 194: 397–402. 10.1016/j.atherosclerosis.2006.08.008
Nakachi T, Kosuge M, Hibi K, Ebina T, Hashiba K, Mitsuhashi T, Endo M, Umemura S, Kimura K: C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J 2008, 72: 1953–9. 10.1253/circj.CJ-08-0185
Mitchell AM, Garvey JL, Kline JA: Multimarker panel to rule out acute coronary syndromes in low-risk patients. Acad Emerg Med 2006, 13: 803–6. 10.1111/j.1553-2712.2006.tb01726.x
Lozano T, Ena J, Almenar V, Graells M, Molina J, Antorrena I, de la Guia F: [Evaluation of patients with acute chest pain of uncertain origin by means of serial measurement of high-sensitivity C-reactive protein]. Rev Esp Cardiol 2007, 60: 817–24.
Magadle R, Weiner P, Beckerman M, Berar-Yanay N: C-reactive protein as a marker for active coronary artery disease in patients with chest pain in the emergency room. Clin Cardiol 2002, 25: 456–60. 10.1002/clc.4960251004
Potsch AA, Siqueira Filho AG, Tura BR, Gamarski R, Bassan R, Noqueira MV, Moutinho MA, Silva AC, Villacorta H, campos AL: C-reactive protein diagnostic and prognostic value in patients presenting at the emergency room with chest pain. Arq Bras Cardiol 2006, 87: 275–80.
Kirk JD, Diercks DB, Turnipseed SD, Amsterdam EA: Evaluation of chest pain suspicious for acute coronary syndrome: use of an accelerated diagnostic protocol in a chest pain evaluation unit. Am J Cardiol 2000, 85: 40B-48B. discussion 49B 10.1016/S0002-9149(00)00755-4
Ridker PM, MacFayden J, Libby P, Glynn RJ: Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention; an Intervention Trial Evaluating Rosuvastatin (Jupiter). Am J Cardiol 2010, 106: 204–9. 10.1016/j.amjcard.2010.03.018
Liyan C, Jie Z, Yonghua W, Xiaozhou H: Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008, 22: 45–9. 10.1002/jcla.20223